{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T11:23:11Z","timestamp":1649071391554},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1528,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1038\/ki.2011.260","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T12:47:10Z","timestamp":1312980430000},"page":"793-796","source":"Crossref","is-referenced-by-count":5,"title":["New clinical trials with vitamin D and analogs in renal disease"],"prefix":"10.1016","volume":"80","author":[{"given":"Rajiv","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2011.260_rf0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0889-8529(18)30339-6","article-title":"Renal osteodystrophy","volume":"19","author":"McCarthy","year":"1990","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1038\/ki.2011.260_bb0015","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","article-title":"KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD)","volume":"55","author":"Uhlig","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.260_bb0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1681\/ASN.2010020186","article-title":"The regulation of parathyroid hormone secretion and synthesis","volume":"22","author":"Kumar","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.260_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1681\/ASN.V1130","article-title":"Vitamin D metabolism and mechanisms of calcium transport","volume":"1","author":"Kumar","year":"1990","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.260_bb0030","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2011.260_bb0035","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","article-title":"A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia","volume":"26","author":"Slatopolsky","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.260_bb0040","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.260_bb0045","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.ki.5002406","article-title":"Differential effects of vitamin D receptor activators on vascular calcification in uremic rats","volume":"72","author":"Mizobuchi","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.260_bb0050","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/ki.2011.226","article-title":"No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial","volume":"80","author":"Hansen","year":"2011","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.260_bb0055","first-page":"72","article-title":"Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis","volume":"35","author":"Kimura","year":"1991","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2011.260_bb0060","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/0003-4819-105-5-649","article-title":"Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism","volume":"105","author":"Resnick","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1038\/ki.2011.260_bb0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2011.260_bb0070","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1038\/ki.2011.260_bb0075","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/j.ajkd.2007.12.038","article-title":"Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial","volume":"51","author":"Szeto","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.260_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.ajkd.2007.04.015","article-title":"25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III)","volume":"50","author":"de Boer","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.260_bb0085","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/ki.2011.224","article-title":"Oral cholecalciferol decreases albuminuria and urinary TGF-\u03b21 in patients with type 2 diabetic nephropathy on established renin\u2013angiotensin\u2013aldosterone system inhibition","volume":"80","author":"Kim","year":"2011","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2011.260_bb0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2003.09.026","article-title":"Measured and estimated GFR in healthy potential kidney donors","volume":"43","author":"Rule","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2011.260_bb0095","series-title":"Kidney Int","article-title":"Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate","author":"Agarwal","year":"2011"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815551466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815551466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T04:00:59Z","timestamp":1638244859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815551466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0085253815551466"],"URL":"https:\/\/doi.org\/10.1038\/ki.2011.260","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}